2014 All Hands Meeting
November 7th Main Session
Life Sciences Track Agenda
Ellen Darling & Carol Pratt
K&L Gates LLP
Life Science Corporate, Commercial & IP Update
Gabriel Gross, Judith Hasko & Mark Roeder
Latham & Watkins LLP
They Said Our Drug or Biologic is “Suspect” What Now?
Christina Markus & Elaine Tseng
King & Spalding
Effective January 1, 2015, the Drug Supply Chain and Security Act (“DSCSA”) places new obligations on pharmaceutical and biopharmaceutical manufacturers and distributors to quarantine and investigate “suspect” products, and to notify both regulators and trading partners about “illegitimate” products identified in the supply chain. This panel will lead a case study to help in-house counsel advise on the new regulatory obligations, evaluate whether operating systems are structured to support compliance, and consider whether contractual relationships and business terms should be updated to streamline communications, coordinate activities, and allocate risks.
LS Privacy Update
Morrison & Foerster LLP
A discussion of privacy, behavioral advertising, cyber-security, and many other topics related to information management by life science companies.
Please Note: Program details are subject to change without notice